GlassScriptPhysician profile
Caleb N Pace
NPI 1124548086
$7,928.79
in general payments reported to CMS, 2019-2025
19 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 80% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $108 · 2021: $2,019 · 2022: $1,909 · 2023: $677 · 2024: $679 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,130 · Travel and Lodging: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.38 |
| Travel and Lodging | $893.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $1,894.02 | 2021-2024 | |
| Stryker Corporation | $1,421.35 | 2019-2024 | Prostep, Easyfuse, Ortholoc 2 Lapifuse |
| Titan Surgical Group, LLC | $1,299.01 | 2022-2025 | |
| Organogenesis INC. | $1,257.08 | 2020-2025 | Puraply, Apligraf, Puraply Antimicrobial |
| Medical Device Business Services, INC. | $1,007.62 | 2025 | Motoband |
| Depuy Synthes Sales INC. | $180.93 | 2025 | Motoband |
| Convatec INC. | $162.02 | 2024 | |
| Mallinckrodt Hospital Products INC. | $155.61 | 2022-2025 | Acthar |
| Horizon Therapeutics Plc | $136.75 | 2023 | Krystexxa |
| Amgen INC. | $86.22 | 2024-2025 | Uplizna, Krystexxa |
| Merck Sharp & Dohme LLC | $66.05 | 2023-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Abbvie INC. | $48.63 | 2022-2023 | |
| Smith+Nephew, INC. | $43.61 | 2022-2023 | Pico 7 |
| Novartis Pharmaceuticals Corporation | $42.25 | 2022 | |
| Melinta Therapeutics, LLC | $30.24 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $26.44 | 2025 | |
| Hydrofera LLC | $24.42 | 2025 | Hydrofera Blue |
| Averitas Pharma INC. | $24.20 | 2023 | Qutenza |
| Coloplast Corp | $22.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.